Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19209892 | 0.87 | EPHX1 (0.47) | EPHX1TRPM8TRPA1KCNA5TRPV1 | |
| SCHEMBL694115 | 0.86 | EPHX1 (0.51) | EPHX1TRPM8TRPA1TRPV1CYP19A1 | |
| SCHEMBL15468048 | 0.86 | EPHX1 (0.44) | EPHX1TRPM8TRPA1KCNA5TRPV1 | |
| SCHEMBL583665 | 0.86 | EPHX1 (0.44) | EPHX1TRPM8TRPA1KCNA5TRPV1 | |
| SCHEMBL4314193 | 0.85 | EPHX1 (0.43) | EPHX1TRPM8TRPA1 | |
| SCHEMBL4312363 | 0.84 | EPHX1 (0.47) | EPHX1TRPM8TRPA1KCNA5TRPV1 | |
| SCHEMBL584085 | 0.83 | EPHX1 (0.46) | EPHX1TRPM8TRPA1KCNA5TRPV1 | |
| SCHEMBL120127 | 0.81 | EPHX1 (0.45) | EPHX1TRPM8TRPA1KCNA5TRPV1 | |
| SCHEMBL8743483 | 0.80 | EPHX1 (0.50) | EPHX1TRPM8TRPA1KCNA5TRPV1 | |
| SCHEMBL38660082 | 0.80 | EPHX1 (0.50) | EPHX1TRPM8TRPA1KCNA5TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3817575-B1 | SOLUBILISATION OF COOLING AGENTS OF LOW SOLUBILITY | SYMRISE AG (DE) | 2025-10-15 | — | — | EP | claimed |
| CN-112384077-A | Solubilization of poorly soluble cooling substances | 西姆莱斯有限公司 | 2021-02-19 | — | — | CN | claimed |
| US-10173966-B2 | Physiological cooling compounds | SYMRISE, INC. (US) | 2019-01-08 | — | — | US | claimed |
| US-20180179147-A1 | PHYSIOLOGICAL COOLING COMPOUNDS | SYMRISE, INC. | 2018-06-28 | — | — | US | claimed |
| EP-3303281-A1 | PHYSIOLOGICAL COOLING COMPOUNDS | Symrise, Inc. (US) | 2018-04-11 | — | — | EP | claimed |
| US-20160355463-A1 | PHYSIOLOGICAL COOLING COMPOUNDS | SYMRISE, INC. | 2016-12-08 | — | — | US | claimed |
| WO-2016196751-A1 | PHYSIOLOGICAL COOLING COMPOUNDS | PINOVA HOLDINGS, INC. (US) | 2016-12-08 | — | — | WO | claimed |
| US-10981862-B2 | Physiological cooling compounds | SYMRISE, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| CN-112384077-A | Solubilization of poorly soluble cooling substances | 西姆莱斯有限公司 | 2021-02-19 | — | — | CN | disclosed |
| US-10173966-B2 | Physiological cooling compounds | SYMRISE, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180179147-A1 | PHYSIOLOGICAL COOLING COMPOUNDS | SYMRISE, INC. | 2018-06-28 | — | — | US | disclosed |
| EP-3303281-A1 | PHYSIOLOGICAL COOLING COMPOUNDS | Symrise, Inc. (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20160355463-A1 | PHYSIOLOGICAL COOLING COMPOUNDS | SYMRISE, INC. | 2016-12-08 | — | — | US | disclosed |
| WO-2016196751-A1 | PHYSIOLOGICAL COOLING COMPOUNDS | PINOVA HOLDINGS, INC. (US) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981862-B2 | Physiological cooling compounds | TAS2R8, TAS2R3, TAS2R1 | EPHX1 2251/4885TRPM8 29/4885TRPA1 31/4885 |
| US-10173966-B2 | Physiological cooling compounds | TAS2R8, TAS2R3, TAS2R1 | EPHX1 2251/4885TRPM8 29/4885TRPA1 31/4885 |
| US-20160355463-A1 | PHYSIOLOGICAL COOLING COMPOUNDS | TAS2R8, TAS2R3, TAS2R1 | EPHX1 2251/4885TRPM8 29/4885TRPA1 31/4885 |
| US-20180179147-A1 | PHYSIOLOGICAL COOLING COMPOUNDS | TAS2R8, TAS2R3, TAS2R1 | EPHX1 2251/4885TRPM8 29/4885TRPA1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.